Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21).
Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21).
复制标题
通过定量流式细胞术鉴定白血病相关的变化。
作者：
By Anna Porwit;G. Janossy;Kamal Ivory;David Swirsky;Rowayda Peters;K. Wheatley;Helen Walker;Alev Turker;A. H. Goldstone;Alan K. Burnett
在医学研究理事会（MRC）AML 10试验的517例急性髓性白血病（AML）的免疫诊断中，我们观察到CD 34前体细胞抗原在M2形态的AML中更常见，尤其是在84%的t（8;21）染色体易位的病例中，比任何其他法-美-英分类组更常见。然后定量⑶ 34表达（使用QIFI和Quantum Simply Cellular珠[流式细胞术标准品，Research Triangle Park，NC]和⑶ 34+标准细胞）。当比较正常骨髓（BM）前体细胞和白血病原始细胞的CD 34抗体结合能力（ABC）时，显示t（8;21）的AML M2病例不仅具有最高的CD 34+原始细胞百分比，而且在> 80%的CD 34+病例中，单个原始细胞表达高于正常水平的CD 34抗原（每个细胞> 60 × 10（3）ABC）。此外，在73%的这组CD 34抗原过表达的异步组合与细胞质髓过氧化物酶（MPO）。其他的免疫缺陷症状包括CD 34与CD 15和/或CD 56的高表达，以及CD 13与末端脱氧核苷酸转移酶（TdT）和CD 19的异常组合。这些发现表明，在几乎每一个有t（8;21）的AML病例中，都可以识别出HLA-Y，尽管它并不总是涉及相同的抗原。M2型伴t（8; 21），主要是CD 34+，有100%的缓解率和71%的5年生存率;其他患者与CD 34+或CD 34- AML分别显示69%和84%的缓解率和31%和36%的5年生存率。因此，单个标记物如CD 34应与其他特征如染色体变化相关进行解释。这些简单的方法非常适合于定量配体的表达，对诊断有很大的贡献：60%至65%的t（8;21）M2病例仅通过CD 34过表达即可快速识别。这种畸变，连同其他表现为白血病的体征，可用于寻找治疗后的残留白血病。
During the immunodiagnosis of 517 cases of acute myelogenous leukemia (AML) entered into the Medical Research Council (MRC) AML 10 trials, we have observed the CD34 precursor cell antigen more frequently in AML of M2 morphology, especially in the 84% of cases with the t(8;21) chromosomal translocation, than in any other French-American-British classification group. CD34 expression was then quantified (using QIFI and Quantum Simply Cellular beads [Flow Cytometry Standards, Research Triangle Park, NC] and CD34+ standard cells). When CD34 antibody-binding capacity (ABC) of normal bone marrow (BM) precursors and leukemic blasts was compared, it was shown that AML M2 cases with t(8;21) not only had the highest percentages of CD34+ blasts, but in > 80% of CD34+ cases the individual blasts expressed higher than normal levels of CD34 antigen (> 60 x 10(3) ABC per cell). In addition, in 73% of this group CD34 antigen was overexpressed in an asynchronous combination with cytoplasmic myeloperoxidase (MPO). Other signs of asynchrony included high CD34 expression with CD15 and/or CD56, as well as aberrant combinations of CD13 with terminal deoxynucleotidyl transferase (TdT) and CD19. These findings demonstrate that asynchrony is identifiable in virtually every case of AML with t(8;21), although it does not always involve the same antigens. M2 cases with t(8;21), mostly CD34+, had a 100% remission rate and 71% 5-year survival rate; other patients with CD34+ or CD34- AML showed 69% and 84% remission rates and 31% and 36% 5-year survival rates, respectively. Consequently, individual markers such as CD34 should be interpreted in relation to other features such as chromosomal changes. These simple methods, which are well suited to quantify the expression of ligands, are a useful contribution to diagnosis: 60% to 65% of M2 cases with t(8;21) are rapidly identified by CD34 overexpression alone. This aberration, together with the other signs of asynchrony seen at presentation, can be used to search for residual leukemia after therapy.
登录
查看更多内容
CD34 恶性成髓细胞表达 N-CAM (CD56) 对于急性髓系白血病微小残留病检测具有重要意义。
影响因子：
11.4
作者：
Coustan-Smith,E;Behm,FG;Hurwitz,CA;Rivera,GK;Campana,D
通讯作者：
Campana,D
慢性和急性髓系白血病中 AML1 基因的 8;21 和 3;21 易位。
DOI：
10.1101/sqb.1994.059.01.068
发表时间：
1994
期刊：
Cold Spring Harbor symposia on quantitative biology
影响因子：
--
作者：
Nucifora,G;Rowley,JD
通讯作者：
Rowley,JD
儿童 t(8;21)(q22;q22) 急性髓细胞白血病的独特免疫表型特征。
影响因子：
20.3
作者：
Hurwitz,CA;Raimondi,SC;Head,D;Krance,R;MirroJr,J;Kalwinsky,DK;Ayers,GD;Behm,FG
通讯作者：
Behm,FG
在含有 (8;21)(q22;q22) 易位的急性髓性白血病中，通过基于 RNA 的聚合酶链反应一致检测到 AML1/ETO 融合转录本。
影响因子：
20.3
作者：
Downing,JR;Head,DR;Curcio-Brint,AM;Hulshof,MG;Motroni,TA;Raimondi,SC;Carroll,AJ;Drabkin,HA;Willman,C;Theil,KS
通讯作者：
Theil,KS
表达正常人造血干细胞膜糖蛋白CD34（MY10）的急性白血病。
影响因子：
11.4
作者：
Vaughan,WP;Civin,CI;Weisenburger,DD;Karp,JE;Graham,ML;Sanger,WG;Grierson,HL;Joshi,SS;Burke,PJ
通讯作者：
Burke,PJ